XTANDI: payments to doctors
Payments that named XTANDI as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $16.6M
- Providers
- 23,553
- Transactions
- 224,568
- Average per transaction
- $74
The per-transaction average — $74 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 23,553 providers the average total is $706, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Astellas Pharma US Inc | $8,304,928 | 49.9% |
| Pfizer | $6,803,296 | 40.9% |
| Astellas Pharma Global Development | $857,947 | 5.2% |
| Astellas Pharma Europe Ltd | $345,256 | 2.1% |
| Astellas Pharma Inc | $157,880 | 0.9% |
| Array Biopharma Inc | $75,291 | 0.5% |
| Medivation Inc. | $43,987 | 0.3% |
| PBG Puerto RICO LLC | $33,127 | 0.2% |
| Astellas US LLC | $8,313 | 0.0% |
| Medivation Services LLC | $210 | 0.0% |
| Pfizer Pharmaceuticals LLC | $201 | 0.0% |
| Astellas Pharma Europe BV | $143 | 0.0% |
| Medivation Field Solutions LLC | $55 | 0.0% |